• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SVP, Finance, & CAO Zakrowski Donald A converted options into 184 shares and covered exercise/tax liability with 82 shares, increasing direct ownership by 3% to 3,526 units (SEC Form 4)

    2/18/26 4:22:56 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Zakrowski Donald A

    (Last) (First) (Middle)
    LILLY CORPORATE CENTER

    (Street)
    INDIANAPOLIS IN 46285

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ELI LILLY & Co [ LLY ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP, Finance, & CAO
    3. Date of Earliest Transaction (Month/Day/Year)
    02/16/2026
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/16/2026 M 184 A $0 3,607.443 D
    Common Stock 02/16/2026 F 81.553(1) D $1,040 3,525.89 D
    Common Stock 1,728.57 I 401(k)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Unit (2) 02/16/2026 M 184 02/16/2026 02/16/2026 Common Stock 184 $0 0 D
    Explanation of Responses:
    1. The reported amount includes 7.458 shares previously withheld to satisfy tax withholding obligations arising prior to the vesting date of this award.
    2. Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
    Remarks:
    /s/ Jonathan Groff for Donald A. Zakrowski, pursuant to authorization on file 02/18/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LLY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    1/7/2026$1250.00Buy
    UBS
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    11/13/2025$1165.00Sector Outperform
    Scotiabank
    11/10/2025$1104.00Market Perform → Outperform
    Leerink Partners
    10/20/2025$840.00 → $930.00Outperform
    BMO Capital Markets
    10/14/2025Hold → Buy
    Erste Group
    More analyst ratings

    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Eli Lilly with a new price target

    UBS resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $1,250.00

    1/7/26 9:11:47 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Eli Lilly from Neutral to Buy and set a new price target of $1,230.00

    12/16/25 8:49:23 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman reiterated coverage on Eli Lilly with a new price target

    Goldman reiterated coverage of Eli Lilly with a rating of Buy and set a new price target of $1,145.00 from $951.00 previously

    12/15/25 10:37:03 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.16% to 2,966 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/18/26 4:27:23 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Luciano Juan R was granted 15 shares, increasing direct ownership by 0.09% to 16,772 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/18/26 4:26:10 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fyrwald J Erik was granted 10 shares, increasing direct ownership by 0.01% to 75,120 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/18/26 4:25:11 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    SEC Filings

    View All

    SEC Form 10-K filed by Eli Lilly and Company

    10-K - ELI LILLY & Co (0000059478) (Filer)

    2/12/26 1:58:32 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ELI LILLY & Co (0000059478) (Filer)

    2/4/26 7:05:22 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly and Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ELI LILLY & Co (0000059478) (Filer)

    11/21/25 4:19:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight

    At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight lossIn a key secondary endpoint, patients taking Taltz and Zepbound were 40% more likely to achieve PASI 100 compared to those taking Taltz alone (40.6% of patients vs. 29.0%, p<0.05)Taltz is the first and only psoriatic disease biologic with data from two trials supporting a potential comprehensive treatment approach alongside an incretin therapy for obesity INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive topline results from the landmark TOGETHER-P

    2/18/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight

    The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others will further propel the market forward.LAS VEGAS, Feb. 17, 2026 /PRNewswire/ -- Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036,

    2/17/26 5:31:00 PM ET
    $ABBV
    $BMY
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company

    Milestone achieved in Scribe and Lilly's ongoing collaboration to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular diseases Achievement validates Scribe's technologies and strengthens momentum across its genetic medicine portfolio, including its internal pipeline advances for cardiovascular and metabolic disease Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives, today announced the achievement of a second success milestone for one of the targets in its collaboration with Eli

    2/17/26 8:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    2/13/24 5:04:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    1/26/24 4:25:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Financials

    Live finance-specific insights

    View All

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

    INDIANAPOLIS, Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.   The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into h

    1/21/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly declares first-quarter 2026 dividend

    INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discov

    12/8/25 2:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care